Studied extensively in patients with wet AMD 1-3 

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD).

MARINA and ANCHOR

HARBOR

VIEW 1 & 2

Safety

Resources
Resources for your patients.
LUCENTIS Co-pay Card Program
Support for your patients with commercial insurance.
LUCENTIS Access Solutions
Genentech Access Solutions is your resource for access and reimbursement support services.